ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Tumor necrosis factor (TNF)"

  • Abstract Number: 0515 • ACR Convergence 2021

    The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts

    Ruby Siegel, Sang Han and Salah-uddin Ahmed, Washington State University, Spokane, WA

    Background/Purpose: Recent unpublished findings from our lab show that the extracellular enzyme sulfatase-2 (Sulf-2) facilitates pro-inflammatory TNF-α signaling which activates rheumatoid arthritis synovial fibroblasts (RASFs).…
  • Abstract Number: 0527 • ACR Convergence 2021

    Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro

    Anil singh, farheen Shaikh and Salah-uddin Ahmed, Washington State University, Spokane, WA

    Background/Purpose: Terminal uridylyl transferase 7 (TUT7), also known as Zcchc6, is a zinc finger domain-containing protein responsible for terminal uridylation of miRNA, implicated in pre-miRNA…
  • Abstract Number: 0931 • ACR Convergence 2021

    Early Improvement in Disease Activity Indices Predicts Achievement of Long-term Clinical Remissions, ASDAS Inactive Disease and Low BASDAI with Normal CRP, During TNF-α-inhibitor Therapy in Patients with Ankylosing Spondylitis

    Sang Jin Lee, Na Ri Kim and Eon Nam, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea

    Background/Purpose: As biologic agents including tumor necrosis factor (TNF)-α inhibitors (TNFi) have been proven to improve enormously clinical outcomes for patients with ankylosing spondylitis (AS),…
  • Abstract Number: 0947 • ACR Convergence 2021

    Cytokine Competent Gut-joint Migratory T Cells Contribute to Inflammation in the Joint

    Adam Lefferts1, David Claypool1, Eric Norman1, Uma Kantheti1 and Kristine Kuhn2, 1University of Colorado, Anschutz Medical Campus, Aurora, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Although studies have identified the presence of gut-associated cells in the enthesis of joints affected by spondyloarthritis, a direct link through cellular transit between…
  • Abstract Number: 0978 • ACR Convergence 2021

    Immunological and Clinical Features of Untreated Juvenile Dermatomyositis Patients with Elevated Neopterin

    Amer Khojah1, Gabrielle Morgan2 and Lauren Pachman3, 1Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 3Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL

    Background/Purpose: Neopterin is a metabolic product of guanosine triphosphate, which is produced by macrophages upon stimulation with interferon-gamma from activated T helper cells. Despite the…
  • Abstract Number: 1016 • ACR Convergence 2021

    Assessment of Pre-Inflammatory Mesenchymal (PRIME) Cells as a Biomarker of Tumor Necrosis Factor-Induced Arthritis in Mice

    Kiana Chen1, Xi Lin1, Lianping Xing2, H. Mark Kenney3, Richard Bell4, Edward Schwarz5 and Homaira Rahimi5, 1University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester Medical Center, Webster, NY, 3University of Rochester Medical Center, Rochester, NY, 4Hospital for Special Surgery, New York, NY, 5University of Rochester, Rochester, NY

    Background/Purpose: Recently, CD45−CD31−Podoplanin (PDPN)+ synovial fibroblast-like cells, termed pre-inflammatory mesenchymal (PRIME) cells were found to be differentially expressed and circulate in the blood of rheumatoid…
  • Abstract Number: 1219 • ACR Convergence 2021

    Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

    Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…
  • Abstract Number: 1338 • ACR Convergence 2021

    Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study

    Philip Mease1, Atul Deodhar2, Joseph Merola3, Iain McInnes4, Deepak Assudani5, Rajan Bajracharya5, Jason Coarse6, Barbara Ink7 and Georg Schett8, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 5UCB Pharma, Slough, United Kingdom, 6UCB Pharma, Raleigh, NC, 7UCB Celltech, Slough, UK, Slough, United Kingdom, 8Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-­17A, and has demonstrated clinical improvements in joint and skin outcomes…
  • Abstract Number: 1429 • ACR Convergence 2021

    ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases

    Stacey Dillon, Lawrence Evans, Katherine Lewis, Jing Yang, Mark Rixon, Joe Kuijper, Daniel Demonte, Janhavi Bhandari, Steven Levin, Kayla Kleist, Sherri Mudri, Susan Bort, Daniel Ardourel, Michelle Seaberg, NinXin Wang, Chelsea Gudgeon, Russell Sanderson, Martin Wolfson, Jan Hillson, Pamela Holland and Stanford Peng, Alpine Immune Sciences, Seattle, WA

    Background/Purpose: B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are TNF superfamily members that bind TACI (transmembrane activator and CAML interactor), BCMA…
  • Abstract Number: 0041 • ACR Convergence 2021

    Vascularized ‘Synovium-on-a-Chip’ – A Novel and Adaptable Model for Dissecting Inflammatory Biology Underlying Rheumatoid Arthritis

    Theresa Wampler Muskardin1, Chao Ma2, Benteng Ma2, Kayla Van Buren3, Timothy Niewold4 and Weiqiang Chen2, 1Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, 2New York University, New York, NY, 3Mnemo Therapeutics, New York, NY, 4Colton Center for Autoimmunity NYU School of Medicine, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a common multisystem inflammatory condition, affecting approximately 1% of the world population. The mechanisms underlying RA are still incompletely defined…
  • Abstract Number: 1855 • ACR Convergence 2021

    Up-regulation of TNFα Gene in Peripheral Blood Is Useful for Predicting the Development of Exercise-induced Pulmonary Hypertension, Which Is Early Stage of Pulmonary Vascular Disease Associated with Systemic Sclerosis

    Yoshinobu Koyama1, Yoshiharu Sato2, Tatsuma Shoji2, Soichiro Fuke1, Takatsune Umayahara1 and Moe Sakamoto1, 1Japanese Red Cross Okayama Hospital, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan

    Background/Purpose: Pulmonary hypertension (PH) is prominent as a vascular involvement of systemic sclerosis (SSc), which remains a leading cause of death in spite of current…
  • Abstract Number: 0507 • ACR Convergence 2020

    Comparison of Secukinumab versus Adalimumab Efficacy by Sex in Psoriatic Arthritis from a Phase 3b, Double-blinded, Randomized, Active-controlled Study

    Grace Wright1, Peter Nash2, Laura Coates3, Jordi Gratacós4, Frank Behrens5, Kevin Ding6, Weibin Bao7, Luminita Pricop6, Corine Gaillez8 and Iain McInnes9, 1Association of Women in Rheumatology, New York, NY, 2School of Medicine Griffith University, Brisbane, Queensland, Australia, 3University of Oxford, Oxford, United Kingdom, 4University Hospital Parc Tauli Sabadell, Barcelona, Spain, 5CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 6Novartis Pharmaceuticals Corporation, East Hanover, 7Novartis Pharmaceuticals Corporation, East Hannover, 8Novartis Pharma AG, Basel, Switzerland, 9Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Lower efficacy to anti-tumor necrosis factor treatment has been reported in female patients with psoriatic arthritis (PsA) as compared to males in clinical registries.1…
  • Abstract Number: 0573 • ACR Convergence 2020

    Effects of Successive Switches of Two Different Biosimilars of Etanercept on Outcomes in Inflammatory Rheumatic Diseases in Daily Practice

    Uta Kiltz1, Styliani Tsiami2, Xenofon Baraliakos1 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: A single switch from an originator to a biosimilar product has been shown to be safe and effective in the treatment of rheumatic musculoskeletal…
  • Abstract Number: 0801 • ACR Convergence 2020

    The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study

    Leslie Harrold1, Keith Wittstock2, Sheila Kelly2, Xue Han2, Joe Zhuo2, Amy Schrader1, Nicole Middaugh1, Page Moore1 and Vadim Khaychuk2, 1Corrona, LLC, Waltham, MA, 2Bristol-Myers Squibb Company, Princeton, NJ

    Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
  • Abstract Number: 0873 • ACR Convergence 2020

    Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Charlie Lovan5 and Alexis Ogdie6, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc., North Chicago, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology